A drug executive collapsed in the Oval Office while President Donald Trump was announcing a deal with drugmakers to reduce prices. Here's what we know.

(Reuters) -Novo Nordisk expects global sales to decline by low-single-digit percentage in 2026 after the drugmaker unveiled a deal on Thursday to slash prices of popular GLP-1 weight‑loss drugs for U.S. government-backed insurance programs and cash payers.

On November 5, 2025, Novo Nordisk reported lower full-year sales and profit guidance following third-quarter results amid slowing growth in its obesity and diabetes businesses, while presenting new clinical data showing Wegovy’s benefits in lowering obesity-related health risks and pursuing regulatory approval for a higher dose.

After a company-wide restructuring costing some DKK 9 billion ($1.38 billion), Novo’s path to success lies in its ability to create the next healthcare-altering drug. This, says Novo CFO Karsten Munk Knudsen, will be the “silver bullet” to defending key markets from competitors.

Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's fortunes.